B Biogen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

in a century. history going on here. welcome to another hour of "america's newsroom." i'm dana perino. >> bill: missed you. happy new year. >> dana: i missed you. are you glad to be back? >> bill: with you absolutely. i'm bill hemmer. happy new year at home. the house is getting ready to end the 117th congress. the senate will do the same later this morning. the new house could convene in about two hours, 12 noon with a vote for speaker expected to begin around 1:00 eastern time. >> dana: five republicans have said they oppose mccarthy for speaker but can only afford to lose four vot...

Drug. now take a look at this from the investigation. it finds that was an unjust fileably high price according to congress. dem democrat is said it is straight up corporate greed. they hope this report will be a wake-up call for the fda to reform. right now the fda is re-evaluating two alzheimer's drugs. one was developed in part by biogen. >> bill: very interesting. gillian turner in washington, d.c. >> dana: as america's crime crisis continues one democrat-led state is making it harder for police to do their jobs. refraction law enforcement. the justice department accused of hiding hundreds...

Deviated from fda guidance and procedures in significant respects. they are accusing the fda of working with biogen, the manufacturer of the drug, to approve the drug, promote it and rush it to market. even putting together joint presentations between the fda and biogen advocating for the drug's effectiveness. the fda not acknowledging any wrongdoing but doubling down on their practices. quote, fda remains committed to the integrity of our drug approval process and will continue to use the accelerated approval pathway that they used here. b biogen says they stand by the integrity of the action...

In July 2020, almost a year before Biogen's dementia medication Aduhelm was approved, the company convened a meeting of advocates and experts to discuss "strategies to help communities of color address dementia."

The first new Alzheimer's treatment in more than 20 years was hailed as a breakthrough when regulators approved it more than four months ago, but its rollout has been slowed by questions about its price and how well it works.